Hi Chad, thanks for the article! Really informative. Just curious, do you recommend selling puts on any particular stocks? Also, what do you think about conservative put investing? By that I mean selling puts way in the money for a very small premium, so essentially there is little probability that you will pick up the shares?

Nevertheless, it was a gamble. I don't like AMZN as a long-term investment because I don't think the company's value proposition is convincing.

I agree with you, to some extent. I sort of took a gamble on an AMZN $310 Jan 17 Call a month or so ago, and it really paid off. Certainly gains to be made on these types of stocks.

Good to know, thanks!

Hi Joshua, any thoughts on where you think AMZN is headed? Just hit a high in intraday trading today. Thanks!

Thanks very much! That helps.

Fantastic article. In addition to Alexis' question, I have a few of my own. I would like to know more about your research on the license termination by Merck for the oral candidate. Any chance you could either construct another article discussing your research or elaborate here?

Also, let's say hypothetically that the FDA rejects the product. Is the company's business sustainable on alternative revenues alone?

4 years stretches far beyond the average review time for such products. Do you attribute this to a lapse in the regulatory process, or is there more to the story beyond the enrollment halt?

Thanks in advance.

Also, I see the PPS consolidating in the next day or so. Very difficult to predict how post-approval stocks will act, but the trend is inherently negative. Look at Arena, Vivus, Orexigen, and Chelsea Therapeutics

Hi Alexis, I believe the stock is down today because shareholders have realized that the extreme cost of the device ($15,000 - $30,000 per unit) could hinder sales uptake. You can read more about this on Bloomberg:

www.bloomberg.com/.../...-full-to-cost-15-000.html

Thanks for commenting! I appreciate your insight, and I completely agree with you. I despise the fact that the said hedge fund is attempting to manipulate shareholders into believing that Ligand has no value, only to squeeze out short term gains on their massive short position. I will say, however, that Ligand is one company that always has something happening. Although there might be a vacuum of fundamental news in respect to the overall market, Ligand should benefit from a myriad of clinical updates for its respective partnerships and collaborations.